ArticleDiabetology & metabolic syndrome2025
Prevalence of MASLD and fibrosis assessed by transient elastography in U.S. adolescents: insights from NHANES 2017-2023.
Article in Diabetology & metabolic syndrome, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Metabolic Dysfunction-Associated Steatotic Liver Disease in Childhood: From Disease Heterogeneity to Personalized Care.Journal of personalized medicine · 2026Review
- Trends in MASLD-related cirrhosis and liver cancer across diverse populations, 2010-2023.Hepatology international · 2026Article
- Development and validation of an explainable machine learning model using routine laboratory biomarkers for identifying prevalent MASLD: Evidence from two observational studies.Clinical and experimental medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
BACKGROUND/
aimsMetabolic dysfunction-associated steatotic liver disease (MASLD) is a common but understudied disease in adolescents. We aimed to estimate the updated prevalence of MASLD and related fibrosis among US adolescents using transient elastography.
methodsThis study analyzed data from the National Health and Nutrition Examination Survey 2017 to March 2020 and August 2021 to August 2023 among adolescents ages 12-19 years. Steatotic liver disease was assessed using the median controlled attenuation parameter (CAP) and fibrosis by median liver stiffness measurement.
resultsA total of 2588 participants were included in the analysis (mean [SD] age, 15.4 [2.3] years; 1366 male participants [52.8%]). The overall age-adjusted prevalence of MASLD was 21.0% (95% CI: 19.1-23.0) using a CAP threshold of ≥ 248 dB/m and 16.1% (95% CI: 14.4-17.8) using ≥ 263 dB/m. The prevalence of MASLD-related fibrosis was 9.0% and 9.7% using CAP thresholds of 248 dB/m and 263 dB/m, respectively. Higher prevalence of MASLD and fibrosis was observed among adolescents with overweight, obesity, and prediabetes. Between the two survey cycles, the age-standardized prevalence of MASLD remained stable, with a non-significant decline observed in the prevalence of fibrosis. Multivariable analysis identified male sex, non-Hispanic Asian ethnicity, increased waist circumference, overweight, and obesity as independent risk factors for MASLD, while waist circumference was the only independent factor associated with MASLD-related fibrosis.
conclusionsIn this cross-sectional study, MASLD and MASLD-related fibrosis were highly prevalent among US adolescents, with significant disparities observed by sex, race, and ethnicity. These findings highlight the substantial burden of MASLD in the adolescent population and underscore the need for continued public health focus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.